Apyx Medical Corporation Stock Price, News & Analysis

Apyx Medical Corporation (NASDAQ:APYX), a leader in advanced energy technology, announced its participation in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston, MA.

CEO Charlie Goodwin and CFO Matt Hill will conduct a fireside chat at 4:00pm ET and hold one-on-one investor meetings throughout the day. The presentation will be available via live webcast with a replay option on the company's investor relations website.

Apyx Medical specializes in Helium Plasma Platform Technology, marketing Renuvion® and AYON Body Contouring System™ for cosmetic surgery and J-Plasma® for hospital surgical markets, with efficacy supported by over 90 clinical publications.

[]

Apyx Medical Corporation (NASDAQ:APYX) has announced the launch of its Renuvion® technology in China, marking a significant expansion into one of the world's largest healthcare markets. The company has entered into a distribution agreement with GlamMoon Medical Technology, a division of BeauCare Clinics Investment Co., Ltd. (BCC), following initial market clearance from China's National Medical Products Administration.

The partnership with BCC, which operates over 60 medical aesthetics hospitals and clinics across 15 Chinese cities, positions Renuvion for significant market penetration. Early clinical interest and completed procedures indicate strong market potential for Apyx's helium plasma technology, which is supported by more than 90 clinical documents.

Apyx Medical Corporation (NASDAQ:APYX), a manufacturer of advanced helium plasma and radiofrequency technology, will release its Q2 2025 financial results on August 7, 2025, after market close. The company will host a conference call at 4:30 PM ET the same day.

Apyx Medical specializes in the Renuvion® and AYON Body Contouring System™ for the cosmetic surgery market, and J-Plasma® for hospital surgical applications. Their technology's effectiveness is backed by over 90 clinical publications, demonstrating their strong presence in the advanced energy technology sector.

Apyx Medical Corporation (NASDAQ: APYX) is showcasing its Renuvion technology at Miami Swim Week, following its successful debut at New York Fashion Week. The event will feature real patients who have undergone Renuvion treatments, demonstrating the technology's effectiveness in addressing loose skin concerns. Renuvion combines helium plasma and radiofrequency energy technology for tissue contraction and collagen remodeling, offering patients a solution for achieving smoother body contours with minimal downtime. The company aims to redefine beauty standards by highlighting authentic transformation stories and empowering individuals through their cosmetic surgery platform. The effectiveness of Renuvion is backed by over 90 clinical documents, positioning it as a trusted tool for plastic surgeons worldwide.

Apyx Medical Corporation (NASDAQ:APYX) has received FDA 510(k) clearance for its innovative AYON Body Contouring System™, the first FDA-cleared all-in-one platform for aesthetic surgical procedures. The system integrates multiple functionalities including fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities. AYON incorporates the company's proprietary Renuvion® technology and features advanced LIFT Technology for real-time adjustments. The initial clearance covers various aesthetic treatments including Renuvion for loose skin, ultrasound-assisted liposuction, and electrocoagulation. Apyx plans to expand AYON's capabilities with an additional 510(k) submission for power liposuction later in 2025. The commercial launch is scheduled for the second half of 2025, targeting key opinion leader surgeons in strategic locations. The company aims to capitalize on the growing demand from over 15 million GLP-1 drug users seeking body contouring solutions.

Apyx Medical Corporation (NASDAQ:APYX) reported Q1 2025 financial results showing mixed performance. Total revenue decreased 8% to $9.4M compared to $10.2M in Q1 2024. The Advanced Energy segment grew 6% to $7.9M, driven by strong generator sales and U.S. single-use handpiece growth of 14%. However, OEM revenue declined 45% to $1.5M. Net loss improved significantly, decreasing 45% to $4.2M from $7.6M year-over-year. The company is preparing to launch its new AYON™ Body Contouring System in H2 2025, pending FDA clearance. The system integrates multiple functions including Renuvion technology, liposuction, and contouring capabilities. For FY2025, Apyx reaffirmed guidance of $47.6M-$49.0M in total revenue.

Apyx Medical Corporation (NASDAQ:APYX) has announced television personality Dolores Catania as Chief of Confidence for their Renuvion brand's Renew You consumer marketing campaign. Catania, known from "The Real Housewives of New Jersey" and "The Traitors," will represent the brand's body contouring technology across marketing initiatives including social media, PR, and physician events.

Renuvion is the only FDA-cleared device for use after liposuction and is backed by over 90 clinical publications. The technology is recognized as the #1 body contouring solution trusted by doctors for addressing loose skin concerns, with 4 out of 5 surgeons agreeing in an independent survey. Catania, who has personal experience with the treatment, will leverage her journey with weight loss and transformation to promote the brand's message of physical and emotional empowerment.

Apyx Medical announced two significant peer-reviewed publications validating the use of their Renuvion technology in abdominal body contouring procedures. The first study, published in Aesthetic Plastic Surgery, was a randomized controlled trial with 76 patients comparing lipoabdominoplasty with and without Renuvion. Results showed higher patient satisfaction and better improvements in skin laxity for the Renuvion group over a 2-year period.

The second study in Aesthetic Surgery Journal Open Forum examined 77 patients undergoing ultrasound-assisted lipoabdominoplasty. The research confirmed that adding Renuvion did not increase complications, despite longer surgical times. Notably, CEO Charlie Goodwin highlighted that with over 15 million patients using GLP-1 drugs, Renuvion is uniquely positioned as the only FDA-cleared device for addressing loose skin post-liposuction in aesthetic procedures.

Apyx Medical (NASDAQ: APYX), manufacturer of proprietary helium plasma and radiofrequency technology Renuvion®, has scheduled its first quarter fiscal year 2025 financial results release for May 8, 2025, before market open.

The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested parties can join via phone (800-717-1738 for domestic, 646-307-1865 for international) using access code 63341, or through the company's webcast link and Investor Relations website section.

Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology marketed as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgical markets. The company's products are supported by over 90 clinical publications.